Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M209425200 on October 24, 2002

J. Biol. Chem., Vol. 277, Issue 52, 50867-50875, December 27, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/52/50867    most recent
M209425200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuzenkova, J.
Right arrow Articles by Severinov, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuzenkova, J.
Right arrow Articles by Severinov, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Mutations of Bacterial RNA Polymerase Leading to Resistance to Microcin J25*

Julia Yuzenkovaabc, Monica Delgadocd, Sergei Nechaevae, Dhruti Savaliaa, Vitaly Epshteinfg, Irina Artsimovitchh, Rachel A. Mooneyi, Robert Landicki, Ricardo N. Fariasd, Raul Salomond, and Konstantin Severinovaj

From the a Department of Genetics, Waksman Institute, Piscataway, New Jersey 08854, d Instituto Superior de Investigaciones Biologicas (Consejo Nacional de Investigaciones y Technicas-Universidad Nacional de Tucuman), 4000 Tucuman, Argentina, f Public Health Research Institute, New York, New York 10016, h Department of Microbiology, Ohio State University, Columbus, Ohio 43210, and i Department of Bacteriology, University of Wisconsin, Madison, Wisconsin 53706

Received for publication, September 13, 2002, and in revised form, October 14, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
CONCLUSIONS
REFERENCES

A mutation in the conserved segment of the rpoC gene, which codes for the largest RNA polymerase (RNAP) subunit, beta ', was found to make Escherichia coli cells resistant to microcin J25 (MccJ25), a bactericidal 21-amino acid peptide active against Gram-negative bacteria (Delgado, M. A., Rintoul, M. R., Farias, R. N., and Salomon, R. A. (2001) J. Bacteriol. 183, 4543-4550). Here, we report that mutant RNAP prepared from MccJ25-resistant cells, but not the wild-type RNAP, is resistant to MccJ25 in vitro, thus establishing that RNAP is a true cellular target of MccJ25. We also report the isolation of additional rpoC mutations that lead to MccJ25 resistance in vivo and in vitro. The new mutations affect beta ' amino acids in evolutionarily conserved segments G, G', and F and are exposed into the RNAP secondary channel, a narrow opening that connects the enzyme surface with the catalytic center. We also report that previously known rpoB (RNAP beta  subunit) mutations that lead to streptolydigin resistance cause resistance to MccJ25. We hypothesize that MccJ25 inhibits transcription by binding in RNAP secondary channel and blocking substrate access to the catalytic center.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
CONCLUSIONS
REFERENCES

Bacterial RNA polymerase (RNAP)1 is the central enzyme of gene expression and a target of genetic regulation. The catalytically proficient core enzyme is composed of five polypeptides: the largest subunit beta ', the second largest subunit beta , the dimer of identical alpha  subunits, and a small subunit omega . Upon the binding of one of the several sigma  specificity subunits the core is converted to a holoenzyme that can specifically initiate transcription from promoters.

RNAP is a target of several inhibitors. Interest is attached to these low molecular weight compounds as they can be used as tools to reveal new information about RNAP mechanism and can also be used as antibacterial drugs. The best studied bacterial RNAP inhibitor, rifampicin, is widely used against mycobacterial infections. Rifampicin and its derivatives bind to the RNAP beta  subunit (1-4) and prevent synthesis of RNAs longer than two-three nucleotides in length by occluding the nascent RNA exit path (5, 6). An unrelated inhibitor, streptolydigin (Stl), either affects the binding of incoming NTP in the substrate binding site of RNAP or directly targets the catalysis of phosphodiester bond formation (7-9). Mutations causing RNAP resistance to Stl were mapped to both the rpoB and rpoC genes, coding for the beta  and beta ' subunits, respectively (3, 10-12). The beta ' site where Stl-resistant substitutions were localized overlaps the site in eukaryal RNAP II largest subunit where substitutions leading to resistance to alpha -amanitin, a peptide that specifically inhibits PNAP II transcription, map (7, 8, 12-15). Thus, Stl and alpha -amanitin may inhibit transcription in their respective systems through similar mechanisms, despite the lack of chemical similarity between the two drugs. The third antibiotic known to target bacterial RNAP, tagetitoxin, inhibits transcription by slowing the rate of RNAP elongation and promoting pausing (16). The site of RNAP that tagetitoxin interacts with is not known. Tagetitoxin also inhibits transcription by eukaryotic RNAP III (17), indicating that the tagetitoxin binding site may be evolutionarily conserved.

Recently, one of our groups (18) reported that Escherichia coli cells harboring a mutation in the rpoC gene, which codes for RNAP beta ', became resistant to microcin J25 (18). Microcin J25 (MccJ25) is a bactericidal peptide made of 21 amino acids (19, 20). MccJ25-producing cells harbor a plasmid that is responsible for MccJ25 production and resistance of MccJ25-producing cells to the drug (21). MccJ25 production increases when cells reach stationary phase and nutrients become limiting, thus giving MccJ25-producing cells an advantage (19, 22).

Most of spontaneous MccJ25-resistant mutants affect genes encoding cytoplasmic membrane proteins and appear to be intake mutants (23). The fact that a rare microcin resistance mutation resulted in altered RNAP suggested that RNAP may be the cellular target of MccJ25. In agreement with this idea, it has been shown that in vitro activity of E. coli RNAP is reduced in the presence of micromolar concentrations of MccJ25 (18).

The rpoC mutation that resulted in MccJ25 resistance caused a substitution of an evolutionarily conserved beta ' Thr931 for Ile. Thr931 is part of segment G, whose sequence is well conserved in largest (beta '-like) RNAP subunits from bacteria to man (15). In the structural model of RNAP core from thermophilic eubacterium Thermus aquaticus a residue equivalent to E. coli beta ' Thr931 is exposed on the inner surface of RNAP secondary channel, a narrow opening that leads from RNAP surface to the catalytic center (24). Based on structural considerations, the secondary channel was hypothesized to direct substrates toward the enzyme active site and to accept the 3'-end-proximal portion of the nascent RNA in transcription elongation complexes that assumed the dead-end conformation (24-26). Thus, the location of the residue affected by rpoC MccJ25 resistance mutation suggests a novel mechanism of RNAP inhibition: occlusion of RNAP secondary channel. Here, we report the isolation of several MccJ25 resistance mutations in evolutionarily conserved segments G, G', and F of cloned E. coli rpoC. The locations of the corresponding beta ' residues on the T. aquaticus RNAP structure are exposed in the inside surface of RNAP secondary channel, strongly supporting the idea that MccJ25 inhibits transcription by binding to and occluding this channel.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
CONCLUSIONS
REFERENCES

Bacterial Techniques and DNA Manipulations-- Plasmids pRW308 (27) and pRL663 (12), overproducing wild-type or C-terminally hexahistidine-tagged beta ' subunit, respectively, were used to obtain MccJ25-resistant mutations. MccJ25 resistant rpoC mutants generated by error-prone PCR were selected from plasmid banks described by Weilbaecher et al. (27). To generate site-specific mutations in segment G, a derivative of pRW308 harboring a unique XhoI site at rpoC codon 943 was created by PCR mutagenesis. The beta ' subunit encoded by the resultant plasmid, pRW308Xho_943, was wild-type because of the degeneracy of the genetic code. The rpoC positions 928, 929, 930, and 931 were next randomized using mutagenic oligonucleotides complementary to rpoC codons 922-946 and incorporating a XhoI site at codon 943. At the site of randomization, positions corresponding to the first and second bases of the codon were equimolar mixtures of A, G, C, and T, whereas positions corresponding to the third base of the codon was an equimolar mixture of G and C. Mutagenic oligonucleotides were used as primers in a PCR reaction with pRW308Xho_943 template. As a second primer, an oligonucleotide whose sequence corresponded to rpoC positions 2534-2555 was used. This primer anneals upstream of a unique pRW308 SalI site located at rpoC position 2629. After amplification, PCR fragments were treated with SalI and XhoI and ligated into appropriately treated pRW308Xho_943. Ligation mixtures were transformed in MccJ25-sensitive DH5alpha E. coli host cells, and transformants were plated on solid LB medium containing 200 µg/ml ampicillin. After overnight growth at 37 °C, recombinant colonies were replica-plated on LB plates containing 200 µg/ml ampicillin, 50 µg/ml MccJ25 (purified as described previously; see Ref. 20), and 1 mM IPTG to derepress the lac promoter that drives expression of plasmid-borne rpoC. MccJ25-resistant colonies were purified, and plasmid DNA was prepared and retransformed into DH5alpha E. coli cells. Transformants were plated on plates containing MccJ25 to confirm that resistance is plasmid-borne. An entire SalI-XhoI rpoC fragment was next sequenced at the Rockefeller University DNA technology center to establish the nature of the mutational change leading to MccJ25 resistance.

To randomize rpoC codons 1136 and 1137 (evolutionarily conserved segment G') we made use of a unique SgrAI recognition site at rpoC position 3402 (codon 1134). Mutagenic oligonucleotides spanned the SgrAI site, as well as positions to be randomized. They were used as primers with pRL663 template and another primer, whose sequence was complementary to rpoC positions 3745-3777. This primer anneals downstream of a unique pRL663 BspEI site located at rpoC position 3639. PCR fragments were treated with SgrAI and BspEI and ligated with appropriately treated pRL663, and MccJ25-resistant clones were selected and confirmed as above. In addition to the SgrAI-BspEI fragment, a portion of rpoC coding for beta ' segments F and G in mutant plasmids was also sequenced, and no changes from the published sequence were observed. Construction of the beta 'Delta (943-1130) mutation will be described elsewhere.2

Preparation of Mutant RNA Polymerases and in Vitro Transcription-- Highly pure RNAP from MccJ25-resistant E. coli SBG231cells (18) and parental MccJ25-sensitive AB259 cells were purified as described (30). RNAP from Xanthomonas oryzae was purified as described in Ref. 31. RNAP from Pseudomonas aeruginosa 8882 strain (provided by Dr. A. Chakrabarty, University of Illinois College of Medicine) was purified by standard E. coli procedure without modifications. Bacillus subtilis RNAP was purified from B. subtilis PolHis cells harboring a genomic rpoC genetically fused to hexahistidine tag (generously provided by Drs. C. P. Moran and G. Schyns, Emory University School of Medicine). RNAP was purified from cell lysates by nickel-nitrilotriacetic acid affinity chromatography followed by ion-exchange on Resource Q (Amersham Biosciences) column. Recombinant RNAP from T. aquaticus was purified from overexpressing E. coli cells as described in Ref. 32. Yeast RNAP II and RNAP III were generous gifts of Dr. Sergei Borukhov (SUNY Brooklyn) and George Kassavetis (UCSD), respectively.

Mutant beta ' Delta (943-1130) RNAP was purified by chitin-affinity chromatography and intein-mediated removal of the chitin binding domain tag, followed by heparin affinity column chromatography, as described elsewhere.2 To partially purify RNAP containing beta ' expressed from a plasmid, E. coli 397C cells (29) were transformed with pRW308, pRL663, or their derivatives, grown at 30 °C in 200 ml of LB medium containing 200 µg/ml ampicillin until A600 of 0.5, induced with 1 mM IPTG for 4 h, collected, disrupted by sonication, and polymin P fractionation was performed as described by Kashlev et al. (28). 1 M NaCl extract of polymin P pellet containing ~10% pure RNAP was precipitated with ammonium sulfate, and precipitate was stored at -80 °C. Before use, an aliquot of ammonium sulfate pellet was dissolved in transcription buffer (40 mM Tris-HCl, pH 7.9, 40 mM KCl, 10 mM MgCl2, 5% glycerol) to give a final protein concentration of ~1 mg/ml, and this preparation was used in transcription assays.

Transcription from the T7 A1 promoter-containing DNA fragment was performed in 10-µl transcription buffer reactions containing 50 ng of DNA, 0.5 µg of wild-type or mutant RNAP, 0.5 mM CpA primer, 2.5 µM alpha -[32P]UTP (300 Ci/mmol), and different concentrations of MccJ25. Reactions proceeded for 10 min at 37 °C and were terminated by the addition of urea-containing loading buffer. Products were analyzed by urea-PAGE electrophoresis (7 M urea, 20% polyacrylamide), followed by autoradiography and PhosphorImager analysis. Transcription from B. subtilis vegA promoter (32) was performed in a buffer containing 40 mM Tris-HCl, pH 7.9, 10 mM MgCl2, 0.1 mM EDTA, 0.1 mM dithiothreitol, 5% glycerol, 25 µg/ml bovine serum albumin using 0.5 mM UpA primer and 2.5 µM alpha -[32P]GTP (300 Ci/mmol) substrate.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
CONCLUSIONS
REFERENCES

RNA Polymerase from Microcin-resistant E. coli Cells Is Resistant to MccJ25 in Vitro-- Earlier, one of our groups (18) reported that E. coli cells harboring the sjmA1 mutation, but not the wild-type E. coli, were able to grow on selective medium containing MccJ25. The sjmA1 mutation was found to correspond to a substitution of Thr931 to Ile in the largest subunit of E. coli RNAP, the beta ' subunit. The original report also established that MccJ25 partially inhibited a steady-state in vitro transcription by the wild-type E. coli RNAP, strongly implying that RNAP is a direct target of MccJ25. However, RNAP harboring the T931I substitution was not tested in these experiments. The experiment presented in Fig. 1 demonstrates that the mutant enzyme is indeed resistant to MccJ25 in vitro. As can be seen, MccJ25 inhibited T7 A1 promoter-directed synthesis of the CpApU abortive RNA product from the CpA dinucleotide primer and radioactively labeled UTP by the wild-type RNAP (compare lanes 4 and 5). In contrast, the CpApU synthesis by RNAP purified from cells harboring the sjmA1 mutation was unaffected by the drug (compare lanes 1 and 2). Order-of-addition experiments established that MccJ25 inhibited abortive RNA synthesis when added either before or after the formation of open promoter complex on the T7 A1 promoter-containing DNA fragment used as a template in this experiment (compare lanes 5 and 6). We therefore conclude that (i) RNAP is a true cellular target of MccJ25, and (ii) MccJ25 does not act by preventing RNAP interaction with DNA.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Transcription inhibition by MccJ25. The indicated E. coli RNAP holoenzymes were combined with the T7 A1 promoter-containing DNA fragment, CpA primer, and [alpha -32P]UTP in the presence and in the absence of 10 µM MccJ25. Reactions were incubated at 37 °C for 15 min, and the products were resolved by denaturing PAGE and revealed by autoradiography. In lanes 2 and 5, MccJ25 was added before promoter complex formation, and in lanes 3 and 6, it was added after promoter complex formation. WT, wild-type.

Additional Substitutions in Conserved Segment G of the beta ' Subunit Lead to MccJ25 Resistance-- The genetic context of the sjmA1 mutation is shown in Fig. 3. As can be seen, the corresponding substitution occurred in a highly conserved segment of the E. coli beta ' subunit, segment G. We hypothesize that the T931I substitution causes MccJ25 resistance by preventing MccJ25 binding to RNAP and that Thr931 is a part of MccJ25 binding site. Given the very high level of evolutionary conservation of segment G, the following two questions are of interest. First, can other MccJ25-resistant mutations in segment G be obtained? Second, will MccJ25 inhibit RNAPs from organisms other than E. coli?

To answer the first question, we obtained plasmids expressing mutant rpoC genes, transformed these plasmids into MccJ25-sensitive E. coli cells, and checked the ability of plasmid-bearing cells to grow on a medium containing MccJ25. In case when growth on selective medium was observed, we purified RNAPs containing mutant beta ' and confirmed that mutant RNAPs were indeed resistant to MccJ25. In cases when no in vivo resistance was observed, we considered the possibility that RNAP containing mutant beta ' could not support cell growth in the presence of MccJ25, when the wild-type, chromosomally encoded RNAP was inactivated. Therefore, RNAPs containing plasmid-borne beta ' were also purified, and their sensitivity to MccJ25 was tested in vitro. All mutants reported below were tested this way. Fig. 2 shows the results of in vivo and complementary in vitro testing with some of the mutants as an example.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   In Vivo and in vitro MccJ25 resistance of plasmid-borne rpoC mutants. A, serial dilutions of the DH5alpha E. coli cells transformed with plasmids expressing the indicated rpoC mutants were spotted on plates in the presence or in the absence of MccJ25. Results of overnight growth are shown. B, RNAP harboring the indicated plasmid-borne beta ' mutations shown in panel A were purified and used in an in vitro transcription assay (see legend for Fig. 1) in the presence or in the absence of 10 µM MccJ25. Reaction products were resolved by denaturing PAGE and revealed by autoradiography (top panel). The residual activity in the presence of MccJ25 was quantified using a PhosphorImager (bottom panel). In the absence on MccJ25, the enzymes demonstrated the following levels of specific activity (calculated as pmol of abortive CpApU product synthesized by 1 pmol of RNAP per min of reaction): wild-type (wt) RNAP, 0.16; RNAPT931I, 0.10; RNAPR933H,A946T, 0.06; RNAPT934M, 0.06; RNAPL1138T, 0.10; RNAPG1137A, 0.06; RNAPS733P, 0.03; and RNAPS793F, 0.03.

A set of several point mutations in segment G of E. coli rpoC cloned on an expression plasmid was recovered in two unrelated screens, one aimed at obtaining termination-altering rpoC mutants (27) and another site-specifically mutating evolutionarily conserved beta ' positions 921 and 935,2 is presented atop of the sequence alignment shown in Fig. 3. MccJ25-sensitive E. coli cells were transformed with plasmids expressing mutant rpoC genes, and the ability of plasmid-bearing cells to grow on MccJ25-containing medium was investigated. As controls, cells harboring plasmids expressing wild-type rpoC or MccJ25-resistant rpoCT931I allele were employed. As expected, cells expressing wild-type rpoC were sensitive to MccJ25, whereas cells expressing the T931I allele were resistant (Fig. 2 and data not shown). Cells harboring expression plasmids bearing the F935S allele were as resistant as control cells expressing rpoCT931I, whereas cells expressing the R933H,A946V double mutant resulted in slow but detectable growth on MccJ25-containing medium (Fig. 2 and data not shown). In contrast, cells expressing Q921P, T934M, and H936Y alleles did not grow on selective medium (Fig. 2 and data not shown).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   Genetic context of rpoCT931I. The heavy bar represents the 1407 amino acid beta ' subunit of E. coli RNAP. Constrictions indicate the sites of natural splits in homologues from chloroplasts and archaea. Hatched boxes labeled from A to H represent segments of beta ' highly conserved in evolution. The amino acid sequences of E. coli beta ' subunit conserved segments G and G' are expanded underneath. Mutations that conferred MccJ25 resistance (either in vivo or in vitro) are shown above the E. coli sequence in red. Mutations that did not confer MccJ25 resistance either in vivo or in vitro are shown in blue. Homologous amino acid sequences from P. aeruginosa (P.a.), X. oryzae (X.o.), B. subtilis (B.s.), T. aquaticus (Taq.), Halobacterium halobium (H.h.), and yeast RNAPs I, II, and III (YP1, YP2, and YP3, respectively) are aligned with the E. coli sequence. The dots symbolize identity to the E. coli sequence, and the hyphens represent gaps. The evolutionarily variable sequence that separates segments G and G' in beta ' subunits from Gram-negative bacteria is shown as a white box. Deletion Delta (943-1130) is shown as a black line above the beta ' subunit and is drawn to scale. Deletion Delta (1045-1098) is shown as a black line above the sequence alignment.

The results of in vitro transcription assays correlated with the in vivo results (Fig. 2) (data not shown). However, the R933H,A946V double mutant, which showed low levels of resistance in vivo, was highly resistant in vitro, suggesting that the mutant RNAP in vivo function is impaired. RNAP harboring the F935S substitution was found to be resistant to the drug, whereas other mutants were sensitive. Three RNAP harboring dominant lethal mutations in segment G, M932L, R933S, and T934A, were also tested for MccJ25 resistance. These mutants were obtained in the course of an independent mutagenesis effort3 and were prepared by in vitro reconstitution.

Additional MccJ25-resistant mutants in segment G were also sought directly. Three rpoC codons immediately to the left of position 931 (928, 929, and 930) were randomized by site-directed PCR mutagenesis, libraries of recombinant plasmids were transformed in MccJ25-sensitive E. coli cells, and MccJ25-resistant clones were selected. As a control, position 931, the site of the original MccJ25-resistant mutation, was also randomized. MccJ25-resistant clones were only obtained in the control mutagenesis reaction. Sequencing of three resistant clones revealed the presence of the original mutation, T931I, as well as two new mutations, T931N and T931L. The corresponding enzymes were also resistant in vitro (data not shown). The result thus suggests that the identity of beta ' amino acids 928-930 is either not important for MccJ25 inhibition, or MccJ25-resistant substitutions at these positions lead to lethal phenotype.

MccJ25 Effect on RNAPs Other Than E. coli-- MccJ25 is effective against Gram-negative bacteria but has no effect on Gram-positive bacteria (19). To determine the specificity of transcription inhibition by MccJ25, we assembled a panel of RNAPs prepared from several Gram-negative and Gram-positive bacteria and compared their ability to perform abortive RNA synthesis in the presence or in the absence of MccJ25 (Fig. 4). In the absence of MccJ25, RNAPs from Gram-negative bacteria demonstrated approximately equal specific activities on the T7 A1 promoter (0.9, 0.6, 1.2, and 0.8 pmol/min of CpApU synthesized by 1 pmol of wild-type E. coli RNAP, E. coli RNAPT931I, P. aeruginosa RNAP, and X. oryzae RNAP, respectively). In agreement with the previously determined in vivo specificity, MccJ25 inhibited abortive synthesis of CpApU from the T7 A1 promoter-containing DNA fragment by RNAPs prepared from three Gram-negative bacteria, wild-type E. coli, X. oryzae, and P. aeruginosa (see Fig. 4; 10, 11, and 9% residual activity in the presence of 25 µM MccJ25, respectively). As expected, E. coli RNAPT931I was active in the presence of 25 µM MccJ25 (85% activity). RNAP from T. aquaticus was assayed on the T7 A1 promoter at 60 °C and was considerably less active (0.2 pmol of CpApU synthesized per min per pmol of enzyme). MccJ25 had no effect on abortive synthesis by recombinant T. aquaticus RNAP at 60 °C (see Fig. 4; 100% activity in the presence of 25 µM MccJ25).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of MccJ25 on transcription by RNAPs from different bacteria. Results of in vitro transcription by the indicated RNAPs in the absence of MccJ25 or in the presence of 8 and 25 µM MccJ25 are shown. In the top panel, abortive transcription was performed from the T7 A1 promoter-containing DNA template using CpA primer and [alpha -32P]UTP to generate the CpApU product. In the bottom panel, transcription was performed from the B. subtilis vegA promoter-containing template using UpA primer and [alpha -32P]GTP to generate UpApG product. WT, wild-type; E.c., E. coli; T. aq., T. aquaticus; P. aer., P. aeruginosa, X. or., X. oryzae; B. sub., B. subtilis.

Because RNAP from B. subtilis displays only a very low level of activity on the T7 A1 promoter (data not shown), we assayed the effect of MccJ25 on this enzyme during the abortive synthesis of UpApG on B. subtilis vegA promoter (32). In the absence of MccJ25, B. subtilis RNAP, E. coli RNAP, and E. coli RNAPT931I demonstrated comparable levels of activity on the vegA promoter (0.8, 0.3, and 0.1 pmol of UpApG synthesized per min per pmol of RNAP, respectively). MccJ25 had no effect on the B. subtilis enzyme (see Fig. 4; 110% activity in the presence of 25 µM MccJ25) and E. coli RNAPT931I (see Fig. 4; 85% activity in the presence of 25 µM MccJ25) but was active against wild-type E. coli enzyme on this promoter (see Fig. 4; 11% activity in the presence of 25 µM MccJ25). Additional experiments demonstrated that MccJ25 had no effect on transcription by yeast RNAPs II and III (data not shown).

Effect of Substitutions in and around Conserved Region G' on MccJ25 Resistance-- Because segment G positions affected by MccJ25-resistant substitutions are identical in beta ' homologues from Gram-positive and Gram-negative organisms, the result implies that other regions of RNAP may also contribute to MccJ25 binding. In RNAP from Gram-negative bacteria, segment G is followed by a long stretch of amino acid sequence that is hypervariable in evolution (33). The hypervariable region is missing in RNAPs from Gram-positive bacteria and eukaryal RNAPs. To test whether the presence of the evolutionarily hypervariable region of beta ' contributes to the MccJ25 sensitivity of RNAP from Gram-negative bacteria, we tested the ability of rpoCDelta (943-1130) allele that lacks the entire hypervariable region and thus resembles homologues from Gram-positive microorganisms to confer MccJ25 resistance in vivo. The mutant beta ' poorly assembles into RNAP, presumably because of its inability to compete with chromosomally encoded wild-type beta '.4 We therefore tested the ability of MccJ25-sensitive cells harboring plasmid pIA331, which, in the presence of IPTG, co-overexpresses wild-type rpoA (alpha ), rpoB (beta ), and rpoCDelta (943-1130) and thus increases the efficiency of the mutant enzyme assembly to grow on MccJ25-containing medium. As controls, plasmid pIA423, which co-overexpresses wild-type rpoA, rpoB, and rpoC, and pRL663rpoC+ and pRL663rpoCT931I plasmids, were used. As can be seen from Fig. 5A, cells harboring pIA331 and pRL663T931I, but not cells harboring pIA423 and pRL663, formed colonies in the presence of MccJ25 and IPTG. Colonies formed by cells harboring pIA331 were minute as compared with colonies formed by cells harboring pRL663rpoCT931I cells, but the efficiency of plating was comparable. Plasmid pIA331, but not other plasmids, significantly inhibited cell growth in the presence of IPTG only, suggesting that RNAPDelta (943-1130) was defective in some cellular function(s) unrelated to MccJ25 resistance. Be that as it may, the results demonstrate that hypervariable region indeed contributes to MccJ25 sensitivity and may be partially dispensable for cell viability at our conditions, because RNAP lacking beta ' residues 943-1130 is presumably the only transcriptionally active enzyme in the presence of MccJ25.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Removal of beta ' hypervariable region leads to low level MccJ25 resistance. A, expression of rpoCDelta (943-1130) allele allows growth in the presence of MccJ25. Indicated serial dilutions of E. coli DH5alpha cultures transformed with plasmids expressing wild-type rpoC (pRL663) and rpoCT931I (pRL663-T931I), co-overexpressing wild-type rpoA, rpoB, and rpoC (pIA423), or co-overexpressing wild-type rpoA, rpoB, and rpoCDelta (943-1130) (pIA331) were spotted on IPTG-containing LB plates in the presence or in the absence of MccJ25. Plates were incubated at 37 °C and photographed after 24 h (in the absence of MccJ25) or after 48 h (in the presence of MccJ25). B, effect of MccJ25 on transcription by E. coli RNAP lacking the beta ' hypervariable region. RNAPDelta (943-1030) was purified, and transcription from the T7 A1 promoter-containing DNA template using CpA primer and [alpha -32P]UTP substrate was performed at increasing concentrations of MccJ25 (from 6.25 to 50 µM). RNAPWT and RNAPT931I were used as controls. Reaction products were resolved by denaturing PAGE and revealed by autoradiography (top). Reaction products were quantified using phosphorimagery, and transcription activity in the presence of MccJ25 was plotted as a percent of the activity in the absence of MccJ25 (bottom).

E. coli RNAPDelta (943-1130) was prepared from cells harboring pIA331 and tested for the ability to transcribe from the T7 A1 promoter in the presence or in the absence of MccJ25 (Fig. 5B). The results showed that the mutant was more resistant to the drug than wild-type E. coli RNAP (26 and 3% residual activity in the presence of 50 µM MccJ25). Because RNAPs from Gram-positive bacteria are highly resistant to MccJ25 in vitro, other sites in these RNAPs must contribute to MccJ25 resistance.

In the beta ' subunits from Gram-negative bacteria, the hypervariable segment is followed by evolutionarily conserved segment G' (33). Because there is no hypervariable region in homologues from Gram-positive bacteria, segments G and G' form a continuous stretch of evolutionary conserved sequence in the beta ' subunits from these organisms (Fig. 3). Segment G residues that cause MccJ25 resistance are part of the so-called G-loop in RNAP structures from thermophilic bacteria of the Thermus genus (24, 34, 35). Residues of segment G' are also part of the G-loop. In particular, Thermus RNAP residues corresponding to E. coli beta ' amino acids 1137 and 1138 are in direct contact with the residue corresponding to E. coli Thr931 and are located at the base of the G-loop. We therefore considered a possibility that substitutions in positions 1137 and 1138 will make E. coli RNAP MccJ25-resistant. Accordingly, codons 1137 and 1138 of plasmid-borne rpoC were randomized, mutant plasmid libraries were transformed in MccJ25-sensitive E. coli, and transformants were plated on selective medium containing MccJ25. No MccJ25-resistant mutants were obtained when codon 1137 was randomized. One clone was picked up at random and found to encode a G1137A substitution; the corresponding RNAP was MccJ25-sensitive in vitro. One resistant clone, coding for L1138T, was recovered from codon 1138 mutagenesis. The corresponding RNAP was purified and found to be MccJ25-resistant in vitro (Fig. 2). Because no changes from the published rpoC sequence in segment G was observed in this mutant (data not shown), we conclude that a substitution in segment G' is indeed responsible for MccJ25 resistance. One MccJ25-sensitive clone from the 1138 mutagenesis reaction was picked up at random and sequenced and found to contain a mutation coding for L1138V substitution. The corresponding RNAP was purified and found to be MccJ25-sensitive in vitro (data not shown).

A functional deletion of beta ' amino acids 1145-1198 immediately to the right of segment G' was described by us previously (33). This deletion did not result in MccJ25 resistance in vivo and in vitro (data not shown).

A double mutation coding for E1030K and I1134D substitutions was isolated in an independent PCR-based screen for termination-altering rpoC mutations (27). The first substitution, of Glu1030, occurred in the hypervariable region; the second substitution, of Ile1134, occurred in segment G'. We tested the ability of plasmid-borne E1030K,I1134D allele to confer MccJ25 resistance in vivo and in vitro and observed no resistance (data not shown). We also looked for additional MccJ25-resistant mutations within the bank of rpoC expression plasmids subjected to error-prone PCR at and around segments G and G' (rpoC codons 876-1213; see Ref. 27). A triple mutation coding for I1115V, G1136D, and F1145S substitutions was recovered in this way. Of the three residues affected, one (beta ' Phe1145) is removed by MccJ25-sensitive Delta (1145-1198) deletion. Substitutions I1115V and/or G1136D are thus likely responsible for MccJ25 resistance. Because I1115V is a conservative substitution, substitution of evolutionarily conserved Gly1136 in segment G' is the probable cause of MccJ25 resistance.

Substitutions in Evolutionarily Conserved Segment F Lead to MccJ25 Resistance-- Residues of beta ' segments G and G' that are important for MccJ25 inhibition are exposed on the surface of narrow RNAP secondary channel that opens on the downstream face of the enzyme and leads to the catalytic site (24). In addition to beta ' segments G and G', conserved segment F also participates in the formation of the secondary channel. We were therefore interested in whether MccJ25-resistant mutations in segment F can be obtained. Toward this end, we tested two segment F mutants, F773I and S793F, that were shown previously to cause resistance to the elongation inhibitor, streptolydigin (12). These mutants did not result in appreciable MccJ25 resistance in vivo or in vitro (Fig. 2) (data not shown). We therefore looked for MccJ25-resistant region F mutants directly, by incorporating an error-prone PCR-amplified rpoC fragment coding for region F (rpoC codons 544-875) into an rpoC expression plasmid, transforming mutant plasmids in MccJ25-sensitive host, and selecting MccJ25-resistant colonies. Several independent MccJ25-resistant colonies were obtained, and the plasmid-borne nature of MccJ25 resistance was confirmed by retransforming of rpoC expression plasmids from MccJ25-resistant clones into sensitive host and replating on selective medium. Four independent clones were obtained, and their sequence at and around segments F, G, and G' was determined. No changes in segment G/G' sequences was detected. In contrast, changes from the published sequence leading to substitutions of segment F residues Ser733 for Pro, Leu783 for Gln, and a double substitution of Leu746 for Pro and Phe773 for Ile were observed (Fig. 6). In vitro analysis confirmed that RNAPs carrying mutations in segment F are resistant to MccJ25 (Fig. 2) (data not shown). We conclude that substitutions in RNAP beta ' segment F lead to MccJ25 resistance.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6.   Mutations in beta ' conserved segment F result in MccJ25 resistance. Genetic context of beta ' segment F. See legend for Fig. 3 for details. Mutations that conferred MccJ25 resistance are shown above the E. coli sequence in red. Mutations that did not confer MccJ25 resistance are shown in blue. E. coli mutation that cause streptolydigin resistance and mutations in eukaryal RNAPs that cause alpha -amanitin resistance are shown above the E. coli sequence.

Stl-resistant Mutations in the beta  Subunit Lead to MccJ25 Resistance-- Substitutions in beta ' segment F that lead to MccJ25 resistance occurred close to segment F sites that, when mutated, cause Stl resistance (12). The main cluster of Stl-resistant mutations is located in the beta  subunit, between Rif clusters I and II (3). To further investigate the relationship between MccJ25 and Stl resistance we tested the ability of E. coli cells expressing several MccJ25-resistant alleles to grow in the presence of Stl, and we tested the ability of cells expressing Stl-resistant rpoB(beta ) alleles to grow in the presence of MccJ25. As expected, cells overproducing Stl-resistant beta ' harboring S793F substitution, as well as cells overproducing Stl-resistant beta  subunit microdeletions Delta (540-544) and Delta (540L545) (3), but not cells overproducing wild-type beta ' or beta , grew on plates containing Stl. Also as expected, cells overproducing partially Stl-resistant beta Delta (535-542) formed minute colonies in the presence of Stl, whereas cells overproducing Stl-sensitive beta Delta (538-540) did not grow (3) (data not shown). None of the segment F, segment G, or segment G' MccJ25-resistant rpoC mutations tested allowed growth on Stl-containing plates (data not shown).

Plating of cells expressing Stl-resistant rpoB alleles on MccJ25 gave an unexpected result. As expected cells expressing rpoCT931I, but not cells expressing wild-type rpoC or Stl-resistant rpoCS793F, grew in the presence of MccJ25 (Fig. 7). Likewise, cells expressing wild-type rpoB and Stl-sensitive rpoBDelta (538-540) did not grow in the presence of MccJ25. In contrast, cells expressing highly Stl-resistant Delta (540-544) and Delta (540L545) grew in the presence of MccJ25, whereas cells expressing low-level Stl resistance allele rpoBDelta (535-542) formed minute colonies. The results of the plating assay were supported by the results of in vitro transcription experiments (data not shown). We also tested several plasmid-borne Rifampicin-resistant rpoB mutants and found that none of them were able to support growth in the presence of MccJ25 (data not shown). We conclude that Stl-resistant mutations in the rpoB gene lead to MccJ25 resistance.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7.   Stl-resistant rpoB mutations cause MccJ25 resistance. E. coli DH5alpha cells transformed with plasmids expressing the indicated rpoC and rpoB alleles were streaked on plates in the presence or in the absence of MccJ25. Results of 30-h growth at 37 °C are shown.


    CONCLUSIONS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
CONCLUSIONS
REFERENCES

The principal result of this work is the demonstration that transcription by mutant RNAP purified from MccJ25-resistant E. coli cells is resistant to MccJ25, whereas transcription by RNAP purified from wild-type cells is MccJ25-sensitive. This result proves that E. coli RNAP is the cellular target of MccJ25. In the best understood case of Rifampicin, mutations toward resistance affect RNAP residues that are removed from each other in primary sequence but that cluster in the enzyme quaternary structure (1-3, 24). Structural analysis demonstrates that Rif-resistance mutation define the Rifampicin binding site (4). We hypothesized that the original MccJ25-resistance mutation, that changed evolutionarily conserved amino acid inside RNAP secondary channel, likewise defines the MccJ25 binding site on RNAP. According to this view, MccJ25 inhibits transcription by binding in the secondary channel and preventing the traffic of NTP substrates to the catalytic center of the enzyme. Indeed, molecular modeling using T. aquaticus RNAP structure and a reported MccJ25 structure (20) shows that 21-amino acid MccJ25 can fit into RNAP secondary channel with little or no steric clashes (data not shown).

If MccJ25 were indeed binding in the secondary channel, it should be possible to isolate additional MccJ25-resistant mutations located in the channel. Further, at least some of these residues must be evolutionarily variable, to explain the observed restriction of MccJ25 action to RNAP from Gram-negative bacteria. Both of these predictions are fulfilled. Here, we report the isolation of additional MccJ25-resistant mutants in segment G, as well as mutations in conserved segments G' and F. Structural analysis indicates that in T. aquaticus RNAP core enzyme structure, residues homologous to those affected in E. coli are exposed in the secondary channel (Fig. 8). As expected, residues in segments G and G' are located close to the original Thr931 and to each other, at the base of the G loop. However, residues in segment F (magenta) are spatially isolated from each other and are located on two opposing sides of the secondary channel, as well as on the roof of the channel. Residues in segments G and G' are identical in RNAPs from Gram-positive and Gram-negative bacteria and therefore could not be responsible for differential action of MccJ25 on these enzymes. On the other hand, residues in segment F are different between RNAPs from Gram-negative and Gram-positive bacteria, and these differences could account for observed specificity of MccJ25 inhibition. In addition, our data indicate that the presence of hypervariable region in beta ' contributes to MccJ25 sensitivity of RNAP from Gram-negative bacteria. The hypervariable region is inserted in RNAP G loop, which appears to be flexible. In T. aquaticus core enzyme structure, G loop is in a "closed" conformation and takes part in the formation of the secondary channel wall (Fig. 8, cyan). In the holoenzyme structure, G loop is in an "open" conformation, turned almost 90 degrees from its position in the core. The opening of the G loop shortens the secondary channel and may affect MccJ25 binding. It is conceivable that the hypervariable region restricts the mobility of the G-loop and thus allows better binding of MccJ25 to RNAP from Gram-negative bacteria.


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 8.   Structural context of MccJ25 resistance mutations. At the top left a backbone representation of T. aquaticus RNAP core is shown. The beta ' subunit is green, and other subunits are white. The active-center Mg2+ is shown in SPACEFILL representation and is colored blue. The boxed area is expanded at the bottom. Amino acid corresponding to E. coli beta ' Thr931 the site of the original MccJ25 mutation (18) is shown in purple and SPACEFILL. Amino acid homologous to E. coli segment G beta ' Phe935 that can be mutated to result in MccJ25 resistance is shown in yellow and SPACEFILL. Amino acid homologous to E. coli segment G' Leu1138 that can be altered to result in MccJ25 resistance is shown in orange and SPACEFILL. The G-loop is shown in cyan. The corresponding loop in RNAPs from Gram-negative bacteria contains an insertion of more than two hundred amino acids (see Fig. 3). Segment F amino acids whose homologues in E. coli beta ' can be altered to result inMccJ25 resistance are shown in magenta. Amino acid homologous to E. coli segment F Ser793 that can be altered to result in Stl resistance is shown in red and SPACEFILL. A stretch of beta  subunit amino acids whose homologues in E. coli can be mutated toward Stl resistance mutation is colored red. The view on the right is perpendicular to the main DNA binding channel of the enzyme and was obtained from the left view by ~90° clockwise rotation around the vertical axis.

Earlier (12), we proposed that the presence of mutations that cause resistance to Stl and alpha -amanitin in conserved segment F of bacterial RNAP beta ' subunits and eukaryal RNAP II largest subunits indicated that the two drugs may function similarly in their respective systems despite the lack of common chemical structure. Here, we show that mutations in beta ' segment F also cause resistance to MccJ25. Amino acids that, when mutated, cause resistance to all three drugs are exposed on the surface of the secondary channel. Analysis of a structural model of bacterial RNAP elongation complex reveals that RNAP secondary channel provides the only unobstructed way from the solvent to RNAP catalytic center, because access from the main DNA binding channel is blocked by nucleic acids (25). Therefore, it is possible that substitutions in the secondary channel can cause resistance to transcription elongation inhibitors whose actual mechanisms of action are different, but all of whom have to pass through the secondary channel to get access to the catalytic center.

Analysis of Stl-resistant rpoB revealed, unexpectedly, that they cause MccJ25 resistance. The result appears to strengthen the idea that MccJ25 and Stl may have a common inhibition mechanism, despite the lack of structural similarity. On the other hand, the presence of MccJ25-resistant mutations in beta  is difficult to reconcile with the notion of MccJ25 binding in the secondary channel, because in RNAP structure, the site of Stl-resistant mutations in the beta  subunit (Fig. 8, red) is located slightly upstream of the catalytic center and should become inaccessible from the secondary channel in the elongation complex (25). Therefore, it is possible that lesions in this site cause MccJ25 resistance indirectly. For example, the G-loop, when opened, may interact with the site of Stl resistance mutations in beta , and Stl resistance mutations could therefore affect the position of the G-loop and thus cause resistance to MccJ25. Alternatively, the beta  Stl site can undergo a conformational change upon transcription complex formation that brings it closer to the secondary channel.

Obviously, further studies will be necessary to determine the site of MccJ25 interaction with RNAP, the mechanism of transcription inhibition by MccJ25, and its relationship, if any, to transcription inhibition by Stl. If MccJ25 were indeed binding in the secondary channel, several very specific predictions concerning the biochemical effects of its interactions with transcription complex could be made. The secondary channel is thought to conduct NTP substrates to the RNAP catalytic center, to accept the 3'-end proximal portion of the nascent RNA in the back-tracked, dead-end conformation of the elongation complex, and to accept transcript cleavage factors GreA and GreB (24). MccJ25 binding should interfere with all of these activities. Experiments aimed at testing these predictions are currently underway.

    ACKNOWLEDGEMENTS

We are grateful to Vladimir Svetlov for the preparation of RNAPDelta (943-1130).

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants GM64307 and GM38660 (to K. S. and R. L., respectively) and by an American Society for Microbiology Arturo Sordelli fellowship (to M. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

b  On leave from the Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia.

c  Contributed equally to this work.

e  Present address: University of California, San Diego, La Jolla, CA.

g  Present address: Dept. of Biochemistry, NYU Medical School, New York, NY.

j  To whom correspondence should be addressed: Waksman Inst., 190 Frelinghuysen Rd., Piscataway, NJ 08854. Tel.: 732-445-6095; Fax: 732-445-5735; E-mail: severik@waksman.rutgers.edu.

Published, JBC Papers in Press, October 24, 2002, DOI 10.1074/jbc.M209425200

2 I. Artsimovitch, V. Svetlov, K. Murakami, and R. Landick, manuscript in preparation.

3 V. Epshtein, A. Mustaev, and A. Goldfarb, submitted for publication.

4 I. Artsimovitch, personal observation.

    ABBREVIATIONS

The abbreviations used are: RNAP, RNA polymerase; Stl, streptolydigin; MccJ25, microcin J25; IPTG, isopropyl-1-thio-beta -D-galactopyranoside.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
CONCLUSIONS
REFERENCES

1. Ovchinnikov, Y. A., Monastyrskaya, G. S., Guriev, S. O., Kalinina, N. F., Sverdlov, E. D., Gragerov, A. I., Bass, I. A., Kiver, I. F., Moiseyeva, E. P., Igumnov, V. N., Mindlin, S. Z., Nikiforov, V. G., and Khesin, R. B. (1983) Mol. Gen. Genet. 190, 344-348[CrossRef][Medline] [Order article via Infotrieve]
2. Jin, D. J., and Gross, C. A. (1988) J. Mol. Biol. 202, 45-58[CrossRef][Medline] [Order article via Infotrieve]
3. Severinov, K., Soushko, M., Goldfarb, A., and Nikiforov, V. (1993) J. Biol. Chem. 268, 14280-14825
4. Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., and Darst, S. A. (2001) Cell 104, 901-912[CrossRef][Medline] [Order article via Infotrieve]
5. McClure, W. R., and Cech, C. L. (1978) J. Biol. Chem. 253, 8949-8956[Abstract/Free Full Text]
6. Schulz, W., and Zillig, W. (1981) Nucleic Acids Res. 9, 6889-6906[Abstract/Free Full Text]
7. Cassani, G., Burgess, R. R., Goodman, H. M., and Gold, L. (1971) Nat. New Biol. 230, 197-200[CrossRef][Medline] [Order article via Infotrieve]
8. Helm, K. v. d., and Krakow, J. S. (1972) Nat. New Biol. 235, 82-83[Medline] [Order article via Infotrieve]
9. McClure, W. R. (1980) J. Biol. Chem. 255, 1610-1616[Abstract/Free Full Text]
10. Lisitsyn, N. A., Sverdlov, E. D., Moiseyeva, E. P., and Nikiforov, V. G. (1985) Bioorg. Khim. 11, 132-134[Medline] [Order article via Infotrieve]
11. Heisler, L. M., Suzuki, H., Landick, R., and Gross, C. A. (1993) J. Biol. Chem. 268, 25369-25375[Abstract/Free Full Text]
12. Severinov, K., Markov, D., Nikiforov, V., Severinova, E., Landick, R., Darst, S. A., and Goldfarb, A. (1995) J. Biol. Chem. 270, 23926-23929[Abstract/Free Full Text]
13. Bartolomei, M., and Corden, J. (1987) Mol. Cell. Biol. 7, 586-594[Abstract/Free Full Text]
14. Bartolomei, M. S., and Corden, J. L. (1995) Mol. Gen. Genet. 246, 778-782[CrossRef][Medline] [Order article via Infotrieve]
15. Allison, L. A., Moyle, M., Shales, M., and Ingles, C. J. (1985) Cell 42, 599-610[CrossRef][Medline] [Order article via Infotrieve]
16. Mathews, D. E., and Durbin, R. D. (1990) J. Biol. Chem. 265, 493-498[Abstract/Free Full Text]
17. Steinberg, T. H., Mathews, D. E., Durbin, R. D., and Burgess, R. R. (1990) J. Biol. Chem. 265, 499-505[Abstract/Free Full Text]
18. Delgado, M. A., Rintoul, M. R., Farias, R. N., and Salomon, R. A. (2001) J. Bacteriol. 183, 4543-4550[Abstract/Free Full Text]
19. Salomon, R. A., and Farias, R. N. (1992) J. Bacteriol. 174, 7428-7435[Abstract/Free Full Text]
20. Blond, A., Cheminant, M., Segalas-Milazzo, I., Peduzzi, J., Barthelemy, M., Goulard, C., Salomon, R., Moreno, F., Farias, R., and Rebuffat, S. (2001) Eur. J. Biochem. 268, 2124-2133[Medline] [Order article via Infotrieve]
21. Solbiati, J. O., Ciaccio, M., Farias, R. N., and Salomon, R. A. (1996) J. Bacteriol. 178, 3661-3663[Abstract/Free Full Text]
22. Chiuchiolo, M. J., Delgado, M. A., Farias, R. N., and Salomon, R. A. (2001) J. Bacteriol. 183, 1755-1764[Abstract/Free Full Text]
23. Salomon, R. A., and Farias, R. N. (1995) J. Bacteriol. 177, 3323-3325[Abstract/Free Full Text]
24. Zhang, G., Campbell, E. A., Minakhin, L., Richter, C., Severinov, K., and Darst, S. A. (1999) Cell 98, 811-824[CrossRef][Medline] [Order article via Infotrieve]
25. Korzheva, N., Mustaev, A., Kozlov, M., Malhotra, A., Nikiforov, V., Goldfarb, A., and Darst, S. A. (2000) Science 289, 619-625[Abstract/Free Full Text]
26. Severinov, K. (2000) Curr. Opin. Microbiol. 3, 118-125[CrossRef][Medline] [Order article via Infotrieve]
27. Weilbaecher, R., Hebron, C., Feng, G., and Landick, R. (1994) Genes Dev. 8, 2913-2927[Abstract/Free Full Text]
28. Kashlev, M., Nudler, E., Severinov, K., Borukhov, S., Komissarova, N., and Goldfarb, A. (1996) Methods Enzymol. 274, 326-334[Medline] [Order article via Infotrieve]
29. Nedea, E. C., Markov, D., Naryshkina, T., and Severinov, K. (1999) J. Bacteriol. 181, 2663-2665[Abstract/Free Full Text]
30. Polyakov, A., Severinova, E., and Darst, S. A. (1995) Cell 8, 365-373
31. Nechaev, S., Yuzhenkova, Y., Niedziela-Majka, A., Heyduk, T., and Severinov, K. (2002) J. Mol. Biol. 320, 11-22[Medline] [Order article via Infotrieve]
32. Le Grice, S. F., Shih, C. C., Whipple, F., and Sonenshein, A. L. (1986) Mol. Gen. Genet. 204, 229-236[CrossRef][Medline] [Order article via Infotrieve]
33. Zakharova, N., Bass, A., Arsenieva, E., Nikiforov, V., and Severinov, K. (1998) J. Biol. Chem. 273, 24912-24920[Abstract/Free Full Text]
34. Vassylyev, D. G., Sekine, S., Laptenko, O., Lee, J., Vassylyeva, M. N., Borukhov, S., and Yokoyama, S. (2002) Nature 417, 712-719[CrossRef][Medline] [Order article via Infotrieve]
35. Murakami, K. S., Masuda, S., and Darst, S. A. (2002) Science 296, 1280-1284[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Bacteriol.Home page
S. B. Socias, P. A. Vincent, and R. A. Salomon
The Leucine-Responsive Regulatory Protein, Lrp, Modulates Microcin J25 Intrinsic Resistance in Escherichia coli by Regulating Expression of the YojI Microcin Exporter
J. Bacteriol., February 15, 2009; 191(4): 1343 - 1348.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. Pavlova, J. Mukhopadhyay, E. Sineva, R. H. Ebright, and K. Severinov
Systematic Structure-Activity Analysis of Microcin J25
J. Biol. Chem., September 12, 2008; 283(37): 25589 - 25595.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
M. F. Pomares, P. A. Vincent, R. N. Farias, and R. A. Salomon
Protective Action of ppGpp in Microcin J25-Sensitive Strains
J. Bacteriol., June 15, 2008; 190(12): 4328 - 4334.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
A. Bellomio, P. A. Vincent, B. F. de Arcuri, R. N. Farias, and R. D. Morero
Microcin J25 Has Dual and Independent Mechanisms of Action in Escherichia coli: RNA Polymerase Inhibition and Increased Superoxide Production
J. Bacteriol., June 1, 2007; 189(11): 4180 - 4186.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Friedman, J. D. Alder, and J. A. Silverman
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2137 - 2145.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
R. E. de Cristobal, J. O. Solbiati, A. M. Zenoff, P. A. Vincent, R. A. Salomon, J. Yuzenkova, K. Severinov, and R. N. Farias
Microcin J25 Uptake: His5 of the MccJ25 Lariat Ring Is Involved in Interaction with the Inner Membrane MccJ25 Transporter Protein SbmA
J. Bacteriol., May 1, 2006; 188(9): 3324 - 3328.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
V. Trinh, M.-F. Langelier, J. Archambault, and B. Coulombe
Structural Perspective on Mutations Affecting the Function of Multisubunit RNA Polymerases
Microbiol. Mol. Biol. Rev., March 1, 2006; 70(1): 12 - 36.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
E. Semenova, Y. Yuzenkova, J. Peduzzi, S. Rebuffat, and K. Severinov
Structure-Activity Analysis of Microcin J25: Distinct Parts of the Threaded Lasso Molecule Are Responsible for Interaction with Bacterial RNA Polymerase
J. Bacteriol., June 1, 2005; 187(11): 3859 - 3863.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
M. A. Delgado, P. A. Vincent, R. N. Farias, and R. A. Salomon
YojI of Escherichia coli Functions as a Microcin J25 Efflux Pump
J. Bacteriol., May 15, 2005; 187(10): 3465 - 3470.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Q. Gong, Y. A. Nedialkov, and Z. F. Burton
{alpha}-Amanitin Blocks Translocation by Human RNA Polymerase II
J. Biol. Chem., June 25, 2004; 279(26): 27422 - 27427.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
I. Artsimovitch, C. Chu, A. S. Lynch, and R. Landick
A New Class of Bacterial RNA Polymerase Inhibitor Affects Nucleotide Addition
Science, October 24, 2003; 302(5645): 650 - 654.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
D. J. Craik, N. L. Daly, I. Saska, M. Trabi, and K. J. Rosengren
Structures of Naturally Occurring Circular Proteins from Bacteria
J. Bacteriol., July 15, 2003; 185(14): 4011 - 4021.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/52/50867    most recent
M209425200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuzenkova, J.
Right arrow Articles by Severinov, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuzenkova, J.
Right arrow Articles by Severinov, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement